



17. **Shrader E, for the Study Group.** Equivalence of St. John's wort extract (ZE 117) and fluoxetine. *Int Clin Psychopharmacol* 2000; 15:61–68.
18. **Stevinson C, Ernst E.** Hypericum for depression. An update of the clinical evidence. *Eur Neuropsychopharmacol* 1999; 9:501–505.
19. **Lecrubier Y, Clerc G, Didi R, Kieser M.** Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. *Am J Psychiatry* 2002; 159:1361–1366.
20. **St. John's wort.** In: Physicians Desk Reference for Herbal Medicines 2000. Medical Economics Company, 2000:719–725.
21. **Markowitz JS, Donovan JL, DeVane L, et al.** Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. *JAMA* 2003; 290:1500–1504.
22. **McGuffin M, editor.** Botanical Safety Handbook. Boca Raton, Fla: CRC Press, Inc., 1997:62–63.
23. **Mathijssen R, Verweij J, de Bruijn P, Loos WJ, Sparreboom A.** Effects of St. John's wort on irinotecan metabolism. *J Natl Cancer Inst* 2002; 94:1247–1249.
24. **Mansky P, Straus S.** St. John's wort: more complications for cancer patients (editorial). *J Natl Cancer Inst* 2002; 94:1187–1188.
25. **Schneider RK, Levenson JL.** Update in psychiatry. *Ann Intern Med* 2002; 137:671–677.
26. **Brown RP, Gerbarg PL, Muskin PR.** Complementary and alternative treatments in psychiatry. In: Tasman A, Kay J, Lieberman JA, editors. *Psychiatry Therapeutics*, Second Edition. Southern Gate, West Sussex, England: John Wiley and Sons, Ltd, 2003:449–485.
27. **Whiskey E, Werneke U, Taylor D.** A systematic review and meta-analysis of *Hypericum perforatum* in depression: a comprehensive clinical review. *Int Clin Psychopharmacol* 2001; 16:239–252.
28. **Ernst E.** The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, echinacea, saw palmetto, and kava. *Ann Intern Med* 2002; 136:42–53.
29. **Adams KE, Cohen MH, Eisenberg D, Jonsen AR.** Ethical considerations of complementary and alternative therapies in conventional medical settings. *Ann Intern Med* 2002; 137:660–664.

.....
ADDRESS: Kathleen Franco, MD, Department of Psychiatry, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.

CORRECTION

Asymptomatic hyperparathyroidism

(September 2003)

The article “How should I follow a patient with mildly elevated serum calcium and PTH, but no symptoms?” by Drs. Jennifer Wojtowitz and Christian Nasr (*Cleve Clin J Med* 2003; 70:811–813) contained an error. The article stated that the calcium-

to-creatinine ratio is generally less than 0.01 in familial hypocalciuric hypercalcemia and greater than 0.02 in primary hyperparathyroidism. This should have been the ratio of calcium clearance to creatinine clearance (also known as fractional excretion of calcium). Thanks go to Dr. Juraj Osterman of the University of South Carolina Medical School, Columbia, SC, for pointing this out.